Athenex provides update from FDA Type A meeting regarding oral paclitaxel plus encequidar for the treatment of metastatic breast cancer

6 July 2021 - Athenex today announced that the Company held a Type A meeting with the U.S. FDA during the ...

Read more →

FDA approves first treatment for patients with plasminogen deficiency, a rare genetic disorder

4 June 2021 - Today, the U.S. FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type ...

Read more →

Varian receives FDA breakthrough device designation for its cardiac radioablation system for treatment of refractory ventricular tachycardia

26 May 2021 - Varian's CRA system has been designated a "breakthrough device" by the FDA because of its potential to ...

Read more →

Roche receives FDA approval for Ventana ALK (D5F3) CDx assay to identify lung cancer patients eligible for targeted treatment with Lorbrena (lorlatinib)

9 March 2021 - The Ventana ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted ...

Read more →

Oxford developed COVID-19 vaccine, then scholars clashed over money

21 October 2020 - Early deal with Merck was scotched for fear poor countries would be left out; now university could ...

Read more →

All eyes on a hurdle race for a SARS-CoV-2 vaccine

19 October 2020 - Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed.  ...

Read more →

Investigators propose different measures for biosimilar equivalence

12 May 2020 - Investigators use the HERITAGE trial findings to argue for a more precise way of measuring clinical equivalence ...

Read more →

COVID-19: world needs a global approach to fight: Bill Gates

12 April 2020 - Over the past few weeks, I’ve spoken to dozens of experts about COVID-19, and there’s clear ...

Read more →

Biosimilars and interchangeable biosimilars: licensure for fewer than all conditions of use for which the reference product has been licensed guidance for industry

5 February 2020 - This guidance provides recommendations to applicants seeking licensure under section 351(k) of the Public Health Service Act ...

Read more →

Bristol-Myers Squibb announces submission of biologics license application for CAR T-Cell therapy lisocabtagene maraleucel (liso-cel) to FDA

18 December 2019 - Submission includes data from TRANSCEND NHL 001 trial evaluating liso-cel in patients with relapsed or refractory ...

Read more →

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

17 August 2019 - Roche has priced its personalised cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of ...

Read more →

Was it really a smart move for the FDA to approve a ‘smart pill’ for treating schizophrenia?

18 July 2019 - In late 2017, the FDA approved the first so-called smart pill, ushering in a new era ...

Read more →

FDA approves Merck’s Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for patients with advanced renal cell carcinoma

22 April 2019 - Approval based on results of KEYNOTE-426, where Keytruda in combination with axitinib reduced the risk of death ...

Read more →

CytoDyn reaches historical milestone, submits first of three sections of BLA to FDA for leronlimab (PRO 140) as a combination therapy for HIV

18 March 2019 - FDA previously granted rolling review for BLA. ...

Read more →

Janssen submits application to U.S. FDA seeking approval of Darzalex (daratumumab) combination therapy for patients with newly diagnosed multiple myeloma who are transplant ineligible

12 March 2019 - Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot ...

Read more →